Daiichi considers Japanese experts to help Ranbaxy meet FDA norms

After a recent development, it is believed that Daiichi Sankyo, which is the parent company of Ranbaxy Labs, may allow a team of Japanese technical experts for additional help. This team of experts would be brought in to work with Ranbaxy Labs on the issues related to quality as raised by the USFDA in the last few months.
Few months ago, Ranbaxys Mohali plant was caught in trouble for violation of current good manufacturing practice (GMP) standards, while earlier, plants at Paonta Sahib in Himachal Pradesh and at Dewas in Madhya Pradesh, faced similar GMP compliance issues. The company’s issues range from felony charges to import alert and needs to resolve them at the earliest.

According to the officials at Daiichi, the quality measures in Ranbaxys present manufacturing units would be augmented. They announced that they would continue to provide technical support tot eh company and make use of more experts coming from their home country to work with Ranbaxy to address the issues raised by USFDA. It is also believed that this move may help the company to take appropriate corrective measures and ensure complete compliance with good manufacturing practice (GMP) norms as laid by the USFDA.